Based on the poor outcome of current therapies, we evaluate the activity and tolerability of the combination therapy of trastuzumab plus oral capcitabine in patients with proven HER2 overexpressing advanced pancreatic cancer. This evidence concerns the gene ERBB2 and pancreatic neoplasm.